Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole

Department of Medicine, University of Wisconsin, Madison 53792, USA.

OBJECTIVES: Proarrhythmic effects have been observed with the selective histamine1 (H1) receptor antagonist drug astemizole, a widely prescribed antihistamine. The metabolites of astemizole and those of other antihistamine compounds have not been implicated as causative agents of cardiac arrhythmias. The purpose of this study was to examine whether desmethylastemizole, the principal metabolite of astemizole, blocks delayed rectifier potassium (K+) channels. BACKGROUND: QT interval prolongation and torsade de pointes are associated with astemizole intake and have been ascribed to block the repolarizing K+ currents, specifically the rapidly activating component of the delayed rectifier iKr. Astemizole undergoes extensive first-pass metabolism, and its dominant metabolite, desmethylastemizole, has a markedly prolonged elimination time. We report the clinical observation of QT prolongation and torsade de pointes in a patient with undetectable serum concentrations of astemizole (< 0.5 ng/ml) and "therapeutic" concentrations of desmethylastemizole (up to 7.7 ng/ml or 17.3 nmol/liter). METHODS: The perforated patch clamp recording technique was used to study the effects of desmethylastemizole (20 nmol/liter) on action potentials and iKr in isolated rabbit ventricular myocytes. RESULTS: Desmethylastemizole produced action potential prolongation and the induction of plateau early afterdepolarizations. Under voltage clamp conditions, desmethylastemizole suppressed iKr amplitude by approximately 65%. The drug E-4031 (100 nmol/liter), which selectively blocks iKr, had a similar effect on current amplitude. CONCLUSIONS: Desmethylastemizole, the major astemizole metabolite, blocks the repolarizing K+ current iKr with high affinity. The clinical observation of QT prolongation and torsade de pointes found with astemizole intake may principally be caused by the proarrhythmic effects of its metabolite desmethylastemizole.

This article has been cited by other articles:

				J.-Q. He, Y. Ma, Y. Lee, J. A. Thomson, and T. J. Kamp Human Embryonic Stem Cells Develop Into Multiple Types of Cardiac Myocytes: Action Potential Characterization Circ. Res., July 11, 2003; 93(1): 32 - 39. [Abstract] [Full Text] [PDF]

				D. M. Roden Pharmacogenetics and drug-induced arrhythmias Cardiovasc Res, May 1, 2001; 50(2): 224 - 231. [Abstract] [Full Text] [PDF]

				B. Drolet, A. Emond, B. Pharm, V. Fortin, P. Daleau, G. Rousseau, R. Cardinal, and J. Turgeon Vitamin K Modulates Cardiac Action Potential by Blocking Sodium and Potassium Ion Channels Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 267 - 273. [Abstract] [PDF]

				D. M Roden and J. R Balser A plethora of mechanisms in the HERG-related long QT syndrome: Genetics meets electrophysiology Cardiovasc Res, November 1, 1999; 44(2): 242 - 246. [Full Text] [PDF]

				M. Khalifa, B. Drolet, P. Daleau, C. Lefez, M. Gilbert, S. Plante, G. E. O'Hara, O. Gleeton, B. A. Hamelin, and J. Turgeon Block of Potassium Currents in Guinea Pig Ventricular Myocytes and Lengthening of Cardiac Repolarization in Man by the Histamine H1 Receptor Antagonist Diphenhydramine J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 858 - 865. [Abstract] [Full Text]

				P. D. West, D. K. Martin, J. A. Bursill, K. R. Wyse, and T. J. Campbell Comparative Study of the Effects of Erythromycin and Roxithromycin on Action Potential Duration and Potassium Currents in Canine Purkinje Fibers and Rabbit Myocardium Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(1): 29 - 36. [Abstract] [PDF]

				S. Mohammad, Z. Zhou, Q. Gong, and C. T. January Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride Am J Physiol Heart Circ Physiol, November 1, 1997; 273(5): H2534 - H2538. [Abstract] [Full Text] [PDF]

				P. Yang, H. Kanki, B. Drolet, T. Yang, J. Wei, P. C. Viswanathan, S. H. Hohnloser, W. Shimizu, P. J. Schwartz, M. Stanton, et al. Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes Circulation, April 23, 2002; 105(16): 1943 - 1948. [Abstract] [Full Text] [PDF]